[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543626":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":33,"centralContacts":38,"locations":48,"responsibleParty":64,"collaborators":42,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":42,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":42,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":51,"whyStopped":42,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Kafrelsheikh University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"atorvastatin","ACTIVE_COMPARATOR","The Atorvastatin arm consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, an open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months",[13],"Drug: Atorvastatin 40mg",{"label":15,"type":10,"description":16,"interventionNames":17},"rosuvastatin","The rosuvastatin arm consisted of 300 patients who received 20 mg daily rosuvastatin for 3 months and an open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months",[18],"Drug: Rosuvastatin 20mg",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Atorvastatin 40mg","The atorvastatin group consisted of 300 patients who received 40 mg daily atorvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.",[9],[26],"group A",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Rosuvastatin 20mg","The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.",[15],[32],"group B",[34],{"name":35,"affiliation":36,"role":37},"mohamed G. Zeinhom, MD","neurology department kafr el-sheikh university","PRINCIPAL_INVESTIGATOR",[39,44],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","2001009606828",null,"mohamed_gomaa@med.kfs.edu.eg",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"sherihan R. ahmed, MD","2001113432342","sherihanrezk2016@gmail.com",[49],{"facility":50,"status":51,"city":52,"state":42,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Kafr Elsheikh University Hospital","RECRUITING","Kafr ash Shaykh","33511","Egypt","EG",{"type":57,"coordinates":58},"Point",[59,60],30.93991,31.11174,{"lat":60,"lon":59},[63],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},{"type":37,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Mohamed G. zeinhom, MD","principal investigator","100543626","phase-3-concomitant-use-of-clopidogrel-with-atorvastatin-or-rosuvastatin-in-patients-with-small-vessel-stroke-100543626",false,"NCT06358313","Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke","Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Small Vessel Stroke, a Randomized Controlled Single-blinded Trial","Inclusion Criteria:\n\n* males and females aged 18-75\n* first-ever moderate and small vessel Stroke\n* Patients are not eligible for rt-PA treatment\n\nExclusion Criteria:\n\n* The investigators excluded patients who had rapidly resolving symptoms before imaging results, and patients with a known history of persistent or recurrent CNS pathology (e.g., epilepsy, meningioma, multiple sclerosis, history of head trauma with a residual neurological deficit).\n* the investigators excluded patients who had clinical seizures at the onset of their stroke, as well as those who had symptoms of any major organ failure, active malignancies, or an acute myocardial infarction within the previous six weeks, and those who were on warfarin, regular ticagrelor during the week before admission, or chemotherapy within the previous year.\n* The investigators excluded patients with active peptic ulcers, GIT surgery, bleeding history within the last year, and those with a history of major surgery within the last three months.\n* The investigators ruled out of our trial patients who had a known allergy to the study drugs and those with INR \\> 1.4 or P.T. \\>18 or blood glucose level \\\u003C 50 or \\> 400 mg\u002FDL or blood pressure \\\u003C 90\u002F60 or \\> 185\u002F110 mmHg on admission or Platelets \\\u003C 100,000.\n* The investigators excluded pregnant and lactating patients and those with stroke due to venous thrombosis and stroke following cardiac arrest or profuse hypotension ineligible for our trial.\n* The investigators excluded patients who were regular users of drugs that affect clopidogrel metabolism, such as ketoconazole, dihydropyridine calcium channel blockers, and rifampin.","ALL","18 Years","75 Years",{"count":78,"type":79},600,"ESTIMATED","INTERVENTIONAL",[82],"PHASE3","Along with the current clinical trial, the impact of adding atorvastatin or rosuvastatin in the first 24 hours on the clinical outcomes of first-ever small vessel stroke patients treated with clopidogrel and aspirin assessed through NIHSS, mRS, and possible adverse effects.",[85],"Ischemic Stroke",[9,15,87,88,54],"clopidogrel","stroke","2026-04-20",{"date":91,"type":92},"2026-04-23","ACTUAL",{"date":94,"type":92},"2024-04-10",{"date":96,"type":79},"2026-05-30",{"name":5,"class":6},1]